Karli K. Kondo

Karli K. Kondo

Auto-generated profile, based on publicly available information

Karli K. Kondo

Center for Early Cancer Detection American Cancer Society Atlanta Georgia USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
KMKatherine Mackey
Katherine Mackey
CAChelsea K. Ayers
Chelsea K. Ayers
KKKarli K. Kondo
Karli K. Kondo
SSSomnath Saha
Somnath Saha
SAShailesh M. Advani
Shailesh M. Advani
DKDevan Kansagara
Devan Kansagara
Data suggest that impacts of COVID-19 differ among U.S. racial/ethnic groups. This systematic review evaluates racial/ethnic disparities in SARS-CoV-2 infection rates and COVID-19 outcomes, factors... Background: Data suggest that the effects of coronavirus disease 2019 (COVID-19) differ among U.S. racial/ethnic groups. Purpose: To evaluate racial/ethnic disparities in severe acute respiratory s...

1 November 2023 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
AWAndrew M. D. Wolf
Andrew M. D. Wolf
KOKevin C. Oeffinger
Kevin C. Oeffinger
YSYa-Chen Tina Shih
Ya-Chen Tina Shih
LWLouise C. Walter
Louise C. Walter
TCTimothy R. Church
Timothy R. Church
RSRobert A. Smith
Robert A. Smith
Lung cancer is the leading cause of mortality and person‐years of life lost from cancer among US men and women. Early detection has been shown to be associated with reduced lung cancer mortality. Our objective was to update the American Cancer Society (ACS) 2013 lung cancer screening (LCS) guideline for adults at high risk for lung cancer. The guideline is intended to provide guidance for screening to health care providers and their patients who are at high risk for lung cancer due to a history of smoking. The ACS Guideline Development Group (GDG) utilized a systematic review of the LCS literature commissioned for the US Preventive Services Task Force 2021 LCS recommendation update; a second systematic review of lung cancer risk associated with years since quitting smoking (YSQ); literature published since 2021; two Cancer Intervention and Surveillance Modeling Network‐validated lung cancer models to assess the benefits and harms of screening; an epidemiologic and modeling analysis examining the effect of YSQ and aging on lung cancer risk; and an updated analysis of benefit‐to‐radiation‐risk ratios from LCS and follow‐up examinations. The GDG also examined disease burden data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms. The GDG judged that the overall evidence was moderate and sufficient to support a strong recommendation for screening individuals who meet the eligibility criteria. LCS in men and women aged 50–80 years is associated with a reduction in lung cancer deaths across a range of study designs, and inferential evidence supports LCS for men and women older than 80 years who are in good health. The ACS recommends annual LCS with low‐dose computed tomography for asymptomatic individuals aged 50–80 years who currently smoke or formerly smoked and have a ≥20 pack‐year smoking history ( strong recommendation , moderate quality of evidence ). Before the decision is made to initiate LCS, individuals should engage in a shared decision‐making discussion with a qualified health professional. For individuals who formerly smoked, the number of YSQ is not an eligibility criterion to begin or to stop screening. Individuals who currently smoke should receive counseling to quit and be connected to cessation resources. Individuals with comorbid conditions that substantially limit life expectancy should not be screened. These recommendations should be considered by health care providers and adults at high risk for lung cancer in discussions about LCS. If fully implemented, these recommendations have a high likelihood of significantly reducing death and suffering from lung cancer in the United States.

7 March 2017 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
AMAaron Mendelson
Aaron Mendelson
KKKarli Kondo
Karli Kondo
CDCheryl Damberg
Cheryl Damberg
ALAllison Low
Allison Low
MMMakalapua Motúapuaka
Makalapua Motúapuaka
DKDevan Kansagara
Devan Kansagara
The benefits of pay-for-performance (P4P) programs are uncertain. To update and expand a prior review examining the effects of P4P programs targeted at the physician, group, managerial, or institutional level on process-of-care and patient outcomes in ambulatory and inpatient settings. PubMed from June 2007 to October 2016; MEDLINE, PsycINFO, CINAHL, Business Economics and Theory, Business Source Elite, Scopus, Faculty of 1000, and Gartner Research from June 2007 to February 2016. Trials and observational studies in ambulatory and inpatient settings reporting process-of-care, health, or utilization outcomes. Two investigators extracted data, assessed study quality, and graded the strength of the evidence. Among 69 studies, 58 were in ambulatory settings, 52 reported process-of-care outcomes, and 38 reported patient outcomes. Low-strength evidence suggested that P4P programs in ambulatory settings may improve process-of-care outcomes over the short term (2 to 3 years), whereas data on longer-term effects were limited. Many of the positive studies were conducted in the United Kingdom, where incentives were larger than in the United States. The largest improvements were seen in areas where baseline performance was poor. There was no consistent effect of P4P on intermediate health outcomes (low-strength evidence) and insufficient evidence to characterize any effect on patient health outcomes. In the hospital setting, there was low-strength evidence that P4P had little or no effect on patient health outcomes and a positive effect on reducing hospital readmissions. Few methodologically rigorous studies; heterogeneous population and program characteristics and incentive targets. Pay-for-performance programs may be associated with improved processes of care in ambulatory settings, but consistently positive associations with improved health outcomes have not been demonstrated in any setting. U.S. Department of Veterans Affairs.

5 September 2017 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
SNShannon M. Nugent
Shannon M. Nugent
BMBenjamin J. Morasco
Benjamin J. Morasco
MOMaya E. O'NEil
Maya E. O'NEil
MFMichele Freeman
Michele Freeman
ALAllison Low
Allison Low
DKDevan Kansagara
Devan Kansagara
Cannabis is increasingly available for the treatment of chronic pain, yet its efficacy remains uncertain. To review the benefits of plant-based cannabis preparations for treating chronic pain in adults and the harms of cannabis use in chronic pain and general adult populations. MEDLINE, Cochrane Database of Systematic Reviews, and several other sources from database inception to March 2017. Intervention trials and observational studies, published in English, involving adults using plant-based cannabis preparations that reported pain, quality of life, or adverse effect outcomes. Two investigators independently abstracted study characteristics and assessed study quality, and the investigator group graded the overall strength of evidence using standard criteria. From 27 chronic pain trials, there is low-strength evidence that cannabis alleviates neuropathic pain but insufficient evidence in other pain populations. According to 11 systematic reviews and 32 primary studies, harms in general population studies include increased risk for motor vehicle accidents, psychotic symptoms, and short-term cognitive impairment. Although adverse pulmonary effects were not seen in younger populations, evidence on most other long-term physical harms, in heavy or long-term cannabis users, or in older populations is insufficient. Few methodologically rigorous trials; the cannabis formulations studied may not reflect commercially available products; and limited applicability to older, chronically ill populations and patients who use cannabis heavily. Limited evidence suggests that cannabis may alleviate neuropathic pain in some patients, but insufficient evidence exists for other types of chronic pain. Among general populations, limited evidence suggests that cannabis is associated with an increased risk for adverse mental health effects. U.S. Department of Veterans Affairs. (PROSPERO: CRD42016033623)

21 March 2017 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
JWJessica Weiss
Jessica Weiss
MFMichele Freeman
Michele Freeman
ALAllison Low
Allison Low
RFRochelle Fu
Rochelle Fu
AKAmy Kerfoot
Amy Kerfoot
DKDevan Kansagara
Devan Kansagara
This article has been corrected. The original version (PDF) is appended to this article as a Supplement. Recent guidelines recommend a systolic blood pressure (SBP) goal of less than 150 mm Hg for adults aged 60 years or older, but the balance of benefits and harms is unclear in light of newer evidence. To systematically review the effects of more versus less intensive BP control in older adults. Multiple databases through January 2015 and MEDLINE to September 2016. 21 randomized, controlled trials comparing BP targets or treatment intensity, and 3 observational studies that assessed harms. Two investigators extracted data, assessed study quality, and graded the evidence using published criteria. Nine trials provided high-strength evidence that BP control to less than 150/90 mm Hg reduces mortality (relative risk [RR], 0.90 [95% CI, 0.83 to 0.98]), cardiac events (RR, 0.77 [CI, 0.68 to 0.89]), and stroke (RR, 0.74 [CI, 0.65 to 0.84]). Six trials yielded low- to moderate-strength evidence that lower targets (≤140/85 mm Hg) are associated with marginally significant decreases in cardiac events (RR, 0.82 [CI, 0.64 to 1.00]) and stroke (RR, 0.79 [CI, 0.59 to 0.99]) and nonsignificantly fewer deaths (RR, 0.86 [CI, 0.69 to 1.06]). Low- to moderate-strength evidence showed that lower BP targets do not increase falls or cognitive impairment. Data relevant to frail elderly adults and the effect of multimorbidity are limited. Treatment to at least current guideline standards for BP (<150/90 mm Hg) substantially improves health outcomes in older adults. There is less consistent evidence, largely from 1 trial targeting SBP less than 120 mm Hg, that lower BP targets are beneficial for high-risk patients. Lower BP targets did not increase falls or cognitive decline but are associated with hypotension, syncope, and greater medication burden. U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative. (PROSPERO 2015: CRD42015017677)

10 June 2019 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
BCBrian Chan
Brian Chan
KKKarli Kondo
Karli Kondo
MFMichele Freeman
Michele Freeman
CAChelsea Ayers
Chelsea Ayers
JMJessica Montgomery
Jessica Montgomery
DKDevan Kansagara
Devan Kansagara